Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 5;8(2):145–156. doi: 10.1016/S2468-1253(22)00389-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Rolling geometric mean of NT50 against SARS-CoV-2 wild-type strain (A) and omicron BA.1 (B) and BA.4/5 (C) subvariants, in patients with IBD treated with infliximab or vedolizumab, over time from the third dose of SARS-CoV-2 vaccine

Geometric mean was calculated using a rolling 15-day window (ie, 7 days on either side of the day indicated). The shaded areas show the 95% CIs of the geometric mean. BA.4/5=BA.4 and BA.5. IBD=inflammatory bowel disease. NT50=50% neutralisation titre.